Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Filibuvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Filibuvir SCHEMBL12748294 | 1.00 | TSHR (0.38) | TSHRRECQLPDE10AALDH1A1HTT | |
| Filibuvir SCHEMBL1053035 | 1.00 | TSHR (0.38) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL1581540 | 0.98 | TSHR (0.37) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL12340576 | 0.94 | PDE10A (0.34) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL1581724 | 0.93 | TSHR (0.34) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL1581447 | 0.93 | TSHR (0.41) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL1581419 | 0.92 | TSHR (0.38) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL3988230 | 0.92 | TSHR (0.38) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL3985567 | 0.91 | TSHR (0.37) | TSHRRECQLPDE10AALDH1A1HTT | |
| SCHEMBL14032061 | 0.91 | TSHR (0.35) | TSHRRECQLPDE10AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250032621-A1 | DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATITIS | SeeCure Taiwan Co., Ltd. (TW) | 2025-01-30 | — | — | US | claimed |
| EP-4483906-A1 | DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATITIS | SeeCure Taiwan Co., Ltd. (TW) | 2025-01-01 | — | — | EP | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024017234-A1 | SALT OF HCV INHIBITOR, CRYSTAL FORM OF SALT, PHARMACEUTICAL COMPOSITION OF SALT, AND USE OF SALT | 广东东阳光药业股份有限公司 | 2024-01-25 | — | — | WO | claimed |
| CN-117417327-A | Salt of HCV inhibitor, crystalline form of salt, pharmaceutical composition thereof and use thereof | 广东东阳光药业股份有限公司 | 2024-01-19 | — | — | CN | claimed |
| US-20230372370-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF COVID-19 | Orcosa Inc. (US) | 2023-11-23 | — | — | US | claimed |
| US-11752166-B2 | Combination therapy for treatment of HCV | COCRYSTAL PHARMA, INC. (US) | 2023-09-12 | — | — | US | claimed |
| EP-3790542-B1 | COMBINATION THERAPY FOR TREATMENT OF HCV | COCRYSTAL PHARMA INC (US) | 2023-07-19 | — | — | EP | claimed |
| EP-4114384-A1 | METHODS OF INHIBITING SARS-COV-2 REPLICATION AND TREATING CORONAVIRUS DISEASE 2019 | Pfizer Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| EP-2680859-B1 | COMPOSITIONS, METHODS OF TREATMENT AND DIAGNOSTICS FOR TREATMENT OF HEPATIC STEATOSIS ALONE OR IN COMBINATION WITH A HEPATITIS C VIRUS INFECTION | SCHENTAG JEROME (US) | 2022-04-27 | — | — | EP | claimed |
| US-20220099672-A1 | Method for Treating and/or Preventing Bacteriophage Lysis During Fermentation | LOCUS SOLUTIONS, LLC | 2022-03-31 | — | — | US | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2021176369-A1 | METHODS OF INHIBITING SARS-COV-2 REPLICATION AND TREATING CORONAVIRUS DISEASE 2019 | PFIZER INC. (US) | 2021-09-10 | — | — | WO | claimed |
| EP-4747381-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PD-L1 | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026101522-A1 | 2'-FLUORO-6'METHYLENE CARBOCYCLIC NUCLEOSIDES AND NUCLEOTIDES AND METHODS OF TREATING POXVIRUS INFECTIONS WITH SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-1928878-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007023381-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752166-B2 | Combination therapy for treatment of HCV | HAVCR2, EIF2AK2, SERPINB1 | TSHR 3386/4885RECQL 1797/4885PDE10A 4099/4885 |
| US-20250032621-A1 | DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATITIS | XIAP, BIRC5, BIRC7 | TSHR 3147/4885RECQL 2411/4885PDE10A 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.